**Melatonin and its protective role in attenuating warm or cold hepatic ischaemia/reperfusion injury**

Chenxia Hu\(^1,2\) | Lingfei Zhao\(^3\) | Fen Zhang\(^1,2\) | Lanjuan Li\(^1,2\)

\(^1\)State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

\(^2\)National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

\(^3\)Key Laboratory of Kidney Disease Prevention and Control Technology, Kidney Disease Center, Institute of Nephrology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Correspondence
Lanjuan Li, State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Email: ljli@zju.edu.cn

Funding information
Independent Fund of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University; National Natural Science Foundation of China, Grant/Award Number: 81700553; Zhejiang Basic Public Welfare Research Program, Grant/Award Number: LGF20H030008

**Abstract**

Although the liver is the only organ with regenerative capacity, various injury factors induce irreversible liver dysfunction and end-stage liver disease. Liver resection and liver transplantation (LT) are effective treatments for individuals with liver failure, liver cirrhosis and liver cancers. The remnant or transplanted liver tissues will undergo hepatic ischaemia/reperfusion (IR), which leads to oxidative stress, inflammation, immune injury and liver damage. Moreover, systemic ischaemia induced by trauma, stroke, myocardial ischaemia, haemorrhagic shock and other injury factors also induces liver ischaemia/reperfusion injury (IRI) in individuals. Hepatic IRI can be divided into warm IRI, which is induced by liver surgery and systemic ischaemia, and cold IRI, which is induced by LT. Multiple studies have shown that melatonin (MT) acts as an endogenous free radical scavenger with antioxidant capacity and is also able to attenuate hepatic IRI via its anti-inflammatory and anti-apoptotic capacities. In this review, we discuss the potential mechanisms and current strategies of MT administration in liver surgery for protecting against warm or cold hepatic IRI. We highlight strategies to improve the efficacy and safety of MT for attenuating hepatic IRI in different conditions. After the potential mechanisms underlying the interactions between MT and other important cellular processes during hepatic IR are clarified, more opportunities will be available to use MT to treat liver diseases in the future.

\(^1\) Chenxia Hu and Lingfei Zhao contributed equally to this manuscript.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Cell Proliferation* Published by John Wiley & Sons Ltd.

Cell Proliferation. 2021;54:e13021. https://doi.org/10.1111/cpr.13021
trauma, stroke, myocardial ischaemia, haemorrhagic shock and other injury factors. Pre-existing liver diseases not only directly lead to a high frequency of liver surgery but are also positively correlated with the severity of hepatic IRI. Moreover, obesity, older age and alcoholism can easily impair liver regenerative capacity and result in hepatic steatosis, which is associated with a higher complication index and postoperative mortality after liver surgery. Hepatic IRI can be divided into warm IRI, which is induced by liver surgery and systemic ischaemia, and cold IRI, which is induced by LT. Cessation of hepatic blood supply is always carried out by clamping manoeuvres and inevitably exposes the liver to IR and leads to liver dysfunction in mammals, while restoration of blood flow further exacerbates liver damage to ischaemic liver tissues. In LT, excised liver grafts are stored in cold preservation solutions before LT, which leads to cold IRI in transplants.

Melatonin (MT), namely, N-acetyl-5-methoxytryptamine, was first found to be synthesized from the amino acid tryptophan in the pineal gland and participates in the regulation of sleep promotion, circadian rhythms and neuroendocrine processes. In addition, MT participates in the regulation of energy metabolism, immune function, cardiovascular function, sexual behaviour, the neuropsychiatric system and reproduction. It serves as a potent endogenous free radical scavenger that protects against mitochondrial damage and has beneficial effects on tissue injury by clearing reactive oxygen species (ROS) or reactive nitrogen species (RNS) in vitro and in vivo. In liver tissue, MT was reported to protect against oxidative damage and IRI via upregulation of glutathione (GSH) levels, maintenance of mitochondrial membrane structure and reduction of lipid peroxidation, oxidized glutathione (GSSG) levels and polymorphonuclear infiltration. MT and its metabolites resist inflammation and prevent disturbances in mitochondrial redox reactions, biogenesis, dynamics and mitophagy to further protect against hepatic IRI.

In this review, we discuss the potential mechanisms and current strategies of MT administration in liver surgery for protecting against warm or cold hepatic IRI. Although MT is considered an effective agent with protective effects against hepatic IR, we still highlight strategies to improve the efficacy and safety of MT for attenuating hepatic IRI in different conditions. After the potential mechanisms underlying the interaction between MT and other important cellular processes during hepatic IR are clarified, more opportunities will be available to use MT to treat clinical liver diseases in the future.

2 | MITOCHONDRIAL DYSFUNCTION, INFLAMMATION AND IMMUNE RESPONSES IN HEPATIC IR

Hepatic IR results in liver injury via activation of mitochondrial ROS, inflammation and immune responses (Figure 1). Depletion of blood flow in liver tissue transforms hepatocyte metabolism into anaerobic respiration and disrupts oxidative phosphorylation. Ischaemia limits the mitochondrial electron transport chain and further leads to deposition of electron carriers at the onset of reperfusion. A lack of oxygen supply results in parenchymal cell death as a consequence of metabolic disturbances, including glycogen consumption, adenosine triphosphate (ATP) depletion, xanthine oxidase conversion and intracellular pH reduction. Liver ischaemia also results in imbalances in Ca²⁺, H⁺ and Na⁺ homeostasis and mitochondrial depolarization and finally swelling of sinusoidal endothelial cells (SECs) and Kupffer cells (KCs). Reperfusion reintroduces oxygen into ischaemic tissue, and reperfusion injury is initiated by direct and indirect cytotoxic mechanisms such as oxidative stress injury, inflammation and immune cell recruitment. Oxidative stress promotes the generation of ATP metabolites accompanied by upregulation of superoxide radicals, hydrogen peroxide and hydroxyl radicals. The adaptive immune response and early and massive T-cell recruitment were initiated after the preservation of ischaemic liver grafts in cold stock solution. Following reperfusion in LT recipients, liver grafts easily develop primary nonfunction or impaired primary function in which they undergo microcirculatory dysfunction and pH homeostasis disturbance. IR induces oxidative stress, which causes mitochondrial permeability transition pore (MPTP) opening, resulting in loss of mitochondrial membrane potential, mitochondrial swelling and decreased ATP generation. Oxidative stress further leads to the generation of ROS, inflammatory cytokines, and complement factors and the upregulation of autophagy, endoplasmic reticulum (ER) stress and mitochondrial dysfunction. Although mitochondrial or cytosolic ROS are unable to directly cause cytotoxicity in liver cells, they promote lipid peroxidation and stimulate the release of damage-associated molecular patterns (DAMPs), namely, nuclear protein high-mobility group box 1 (HMGB1). In response to Toll-like receptor 4 (TLR4) on the surface of KCs, HMGB1 migrates from hepatocytes and binds to KCs to activate sterile inflammation and promote the generation of additional ROS. Lipid peroxidation further upregulates the release of cytochrome c into the cytoplasm, the activation of caspases and the initiation of cell death after the upregulation of mitochondrial membrane permeability and the loss of mitochondrial integrity.

Reperfusion-induced inflammation has been reported to induce hepatic IRI in parenchymal and nonparenchymal cells from in situ and transplanted liver grafts. Various inflammatory cells, such as neutrophils, KCs, T lymphocytes, natural killer T (NKT) cells, and various humoral factors, such as complement factors, cytokines and chemokines, are activated to exacerbate injury in SECs and hepatocytes in hepatic IR models. KCs, which are the resident antigen-presenting macrophages in liver tissue, can be first activated for the regulation of downstream inflammatory cells in circulation at the earliest stages of IR. KCs recognize circulating DAMPs to translate alarm signals into an overt inflammatory response. At the initial phase of reperfusion, KC activation enhances the generation of ROS and promotes the release of inflammatory cytokines such as tumour necrosis factor alpha (TNF-α), interleukin (IL)-1 and IL-6. After that, IL-1 and TNF-α activate CD4+ T lymphocytes to generate TNF-β, TNF-γ and granulocyte-macrophage colony-stimulating factor (GM-CSF). In contrast, the pathophysiology of hepatic IR is related to the level of nitric oxide (NO), which is produced by two synthase
isoforms, endothelial NO synthase (eNOS) and inducible NO synthase (iNOS). Hepatic SECs constitutively and exclusively produce small amounts of NO to maintain endothelial function for short intervals, and eNOS contributes to the protective mechanism of the endothelium. However, inflammatory factors significantly increase the activity of iNOS to synthesize large amounts of NO and produce free radicals in hepatocytes, SECs, KCs and hepatic stellate cells (HSCs) for sustained periods. Circulating inflammatory factors also trigger the migration of nonresident neutrophils and monocytes into injured sites and initiate a second wave of ROS/RNS production that exacerbates hypoperfusion and the release of proteases, leading to hepatocyte toxicity. At the late phase of perfusion, recruitment of neutrophils promotes the release of other inflammatory factors from injured sites, which leads to granulocyte accumulation in the sinusoidal space and microcirculatory disturbances.

3 | APOPTOSIS, NECROSIS AND AUTOPHAGY IN HEPATIC IR

Reduced oxidative phosphorylation results in failure of aerobic ATP formation and subsequent cell death of hepatocytes and SECs in anoxic and ischaemic microenvironments. Several cell death modes, including apoptosis, necrosis and autophagy, can be found in liver grafts undergoing warm or cold IR. Mitochondrial dysfunction can induce two modes of cell death: apoptosis and necrosis. Mild injury induces hepatocyte apoptosis, while severe injury induces cell necrosis. Cell apoptosis is a kind of cell death characterized by cell shrinkage, chromatin condensation, nuclear fragmentation and the formation of apoptotic bodies. Necrosis is another kind of cell death characterized by mitochondrial and cell swelling, loss of plasma membrane integrity and vacuolization.
Increased damage or intracellular ATP depletion converts the cell death mechanism from apoptosis to necrosis. Mitochondria-derived ROS increase lipid peroxidation and mitochondrial membrane permeability, ultimately leading to the release of cytochrome c and caspases and the exacerbation of apoptotic cell death. NO production and inflammatory cytokines also disrupt liver microcirculation and mitochondrial function and promote the generation of caspases, cytochrome c and antiapoptotic protein B-cell lymphoma 2 (Bcl-2) to promote hepatocyte necrosis and liver regeneration.

In particular, three types of autophagy, macroautophagy, microautophagy and chaperone-mediated autophagy (CMA), serve as self-digestion methods to remove long-lived proteins, damaged organelles and malformed proteins to supply ATP and nutrients in mammals. Autophagy is reported to be regulated by different signalling pathways, such as the mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), Bcl-2 and p53 pathways. The mTOR signalling pathway is the main potent proinflammatory regulator that negatively regulates autophagy activation. Although autophagy can protect against hepatic IRI by counterbalancing ATP deprivation at the ischaemia stage, there is evidence indicating that sustained and excessive activation of autophagy leads to the progression of cell death at the reperfusion phase. The contradictory effects may be attributed to the fact that different types of IR and different liver conditions lead to different degrees of autophagy activation. To compensate for the lost liver function, all these pathophysiological changes convert injured livers to a regenerative state. Stathmin-mediated mitosis was reported to be activated to promote hepatocyte proliferation around the perivascular regions after IR, and several nonparenchymal cells, such as KCs and HSCs, worked together to participate in liver tissue remodelling. When regeneration is unable to counteract liver injury induced by excessive injury factors, irreversible liver damage will develop into acute or chronic liver failure. As the potential mechanisms underlying hepatic IRI are complex, targeting individual mechanisms makes it difficult to achieve the desired protection in attenuating hepatic IR-induced liver injury.

4 | THE METABOLIC AND SIGNALLING PATHWAYS OF MT IN LIVER TISSUE

The concentration of MT in liver tissue may depend on hepatic metabolic requirements, and this hormone is probably synthesized in the liver and intestinal tract. The level of MT is generally highest in serum, while Lahiri et al documented that the second highest level of MT was in the liver. The gastrointestinal tract releases MT into the portal circulation and liver tissue; moreover, new data suggest that another source of MT is synthesis by the liver. MT is metabolized by cytochrome P450 in liver tissue and is transformed into 6-hydroxymelatonin and N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (AFMK). MT and its metabolites protect against hepatic IRI by directly or indirectly inhibiting oxidative stress, inflammation and immune responses (Figure 2). However, severe oxidative stress promotes the nonenzymatic MT metabolism via its interaction with ROS and NOS. In the subcellular milieu of liver tissue, the MT concentration is highest in the cell membrane since the cell membrane acts as a reservoir of MT. Whenever MT is needed in other subcellular circumstances, MT is transferred from the cell membrane into the cell and from the cytosol to the mitochondria and nucleus. The transport mechanism in the subcellular milieu enables MT to have low toxicity when it is administered in high doses. Reiter and colleagues found that the concentration of MT in mitochondria isolated from rat hepatocytes greatly exceeded that in blood; moreover, pinealectomy did not decrease the level of MT in hepatocytes. This enables MT to act as a paracrine or autocrine factor to regulate intracellular events.

Melatonin also protects against oxidative stress in liver IRI through multiple novel signalling pathways, such as the TLR, haem oxygenase-1 (HO-1) and c-Jun N-terminal kinase (JNK) pathways. Among the numerous pathways, crosstalk between MT and the TLR system in hepatic IRI is pivotal. TLRs are pattern-recognition receptors that recognize conserved pathogen-associated molecular patterns (PAMPs). TLR4 is one of the putative HO-1 repressors in noninfectious hepatic IRI, which indicates that the crosstalk between HO-1 and the TLR4 system is also important in hepatic IRI. Kang and colleagues found that MT effectively inhibited the activation of JNK and extracellular signal-regulated kinase (ERK) signalling, inhibited the nuclear translocation of nuclear transcription factors such as nuclear factor β (NF-κB) and c-Jun, and induced the upregulation of HO-1. HO-1 is the rate-limiting enzyme in haem degradation and has adaptive antioxidative and anti-inflammatory effects in hepatic IRI. MT protected against liver IRI via upregulation of HO-1 and suppression of the IFN signalling pathway downstream of TLR4. After that, MT augmented the level of NF-E2-related factor-2 (Nrf2) nuclear translocation and attenuated the upregulation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 1 (STAT1). Dysregulation of JNK signalling has been suggested to be an important factor in the regulation of metabolism, inflammation and immune responses in the pathology of IRI. Administration of JNK inhibitors and their substrate c-Jun significantly increased the survival rate of experimental models with liver resection and decreased the cell death rate of pericentral hepatocytes and nonparenchymal cells via activation of caspase-3 and inhibition of cytochrome c release and lipid peroxidation.

5 | MT TREATMENTS PROTECT AGAINST HEPATIC IRI

Characterization of hepatic IRI may unlock a novel therapeutic avenue in which ROS overexpression, and sterile inflammatory disorder can be targeted to preserve liver function during the progression of liver IR. MT was recently recognized as an effective factor in preserving liver function in liver grafts undergoing hepatic IRI via its antioxidation, anti-inflammation and antiapoptotic capacities (Table 1).
Melatonin was reported to protect against IRI by improving mitochondrial respiration, ATP synthesis, mitochondrial swelling and lipid peroxidation in liver tissue. Melatonin significantly decreased the malonaldehyde (MDA) level and increased the concentrations of superoxide dismutase (SOD) and GSH in vivo, subsequently down-regulating the levels of alanine transaminase (ALT), aspartate transaminase (AST) and lactate dehydrogenase (LDH) in hepatic IR models. Melatonin can not only decrease the level of lipid peroxidation but also improve mitochondrial glutamate dehydrogenase activity to decrease the rate of mitochondrial swelling and the release of cytochrome c and caspase-3 in hepatic IR rats. Rodriguez-Reynoso et al documented that exogenous MT effectively preserved liver function and energy metabolism in hepatic IR rats by inhibiting the generation of TNF-α, iNOS and NO. MT also served as a hepatoprotective agent for the attenuation of warm liver IRI and improved animal survival time via inhibition of the IκB kinase (IKK) and JNK pathways. Consequently, MT significantly decreased iNOS expression and leucocyte infiltration to enhance cell proliferation and inhibit hepatocyte necrosis. MT pretreatment attenuated liver injury and preserved the levels of liver enzymes in animals with hepatic IR by downregulating serum levels of IL-1β, IL-6, IL-18, TNF-α and IFN-γ but upregulating IL-1Ra. MT was reported to upregulate the phosphorylation of p90RSK and Bad and downregulate the expression of cleaved caspase-3 to protect against hepatic IRI. Furthermore, MT was shown to protect against liver IRI by downregulating autophagic flux and the phosphorylation of mTOR, 4E-BP1 and 70S6K. Intriguingly, Nickkhohlg et al studied 50 patients with liver resection and found
| Animal | IR method | MT dose (mg/kg) | Route        | Effect                                                                 | Mechanism                                                                                                                                                                                                 | Ref. |
|--------|-----------|----------------|--------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Rat    | 70 min ischaemia; 2 h reperfusion | 10          | Intraperitoneal | Protected against mitochondrial injury; decreased mitochondrial lipid peroxidation; increased mitochondrial glutathione peroxidase activity | Reduced mitochondrial oxidative stress; increased respiratory control index; State 3 respiration and dinitrophenol-induced uncoupled respiration; improved hepatic mitochondrial energy transfer and energy metabolism | 26   |
| Rat    | 60 min ischaemia; 1 or 5 h reperfusion | 10          | Intraperitoneal | Reduced the level of serum aminotransferase; ameliorated IR-induced liver damage | Decreased levels of TLR3 and TLR4; decreased serum level of HMGB1; suppressed the expression of MyD88, ERK, NF-κB; suppressed phosphorylated JNK and phosphorylated c-Jun; increased the level of TRIF expression; decreased the phosphorylation of IRF3 and IFN-β; attenuated the levels of TNF-α, IL-6 and iNOS; increased the level of HO-1 | 61   |
| Rat    | 60 min ischaemia; 5 h reperfusion | 10          | Intraperitoneal | Decreased serum ALT activity | Increased HO activity; enhanced the level of Nrf2 nuclear translocation; decreased TLR4, TRIF, and MyD88; suppressed the interaction between TLR4/TRIF and TLR4/MyD88; decreased the levels of JAK2, STAT1 and IFN-β | 62   |
| Rat    | 35 min ischaemia; 2, 4, 8 or 24 h reperfusion | 10          | Intraperitoneal | Downregulated the levels of ALT, AST and LDH | Decreased the level of MDA; increased the levels of SOD and GSH | 65   |
| Rat    | 60 min ischaemia; 5 h reperfusion | 10          | Intraperitoneal | Decreased serum ALT activity and lipid peroxidation; decreased the rate of mitochondrial swelling; decreased the release of cytochrome c and caspase-3 | Improved GSH content and mitochondrial glutamate dehydrogenase activity | 66   |
| Rat    | 60 min ischaemia; 2 h reperfusion | 10          | Intraperitoneal | Improved the survival rate; decreased ALT, AST and lipid peroxidation | Decreased plasma nitrite, TNF-α, and iNOS expression; preserved the hepatic mitochondrial redox status | 67   |
| Rat    | 30 min ischaemia; reperfusion with nonischaemic liver tissue resection | 50          | Gavage        | Improved animal survival rate; decreased transaminase levels; decreased cell necrosis; decreased liver damage | Decreased leucocyte infiltration and iNOS expression; inhibited the IKK and JNK pathways; improved cell proliferation | 68   |
| Rat    | 30 min ischaemia; 2 h reperfusion | 20          | Intraperitoneal | Decreased ALT, AST and LDH levels | Decreased serum levels of IL-1β, IL-6, IL-18, TNF-α and IFN-γ | 69   |
| Rat    | 35 min ischaemia; 2, 4, 8 or 24 h reperfusion | 10          | Intraperitoneal | Decreased necrosis | Decreased liver IL-1β; increased IL-1Ra | 70   |
| Mouse  | 1 h ischaemia; 3 h reperfusion | 10          | Intraperitoneal | Attenuated ALT and AST levels; ameliorated hepatic injury-induced pathologic lesions | Increased the phosphorylation of Raf-1, MEK1/2, and ERK1/2; increased the phosphorylation of p90RSK and Bad | 71   |
| Mouse  | 60 min ischaemia; 0, 1, 5 or 24 h reperfusion | 10          | Intraperitoneal | Decreased hepatocellular damage; decreased ALT and AST; decreased necrosis, sinusoidal congestion and hepatocyte vacuolization | Increased mTOR, 4E-BP1 and 70S6K phosphorylation; decreased autophagic flux; decreased oxidative stress | 72   |

(Continues)
| Animal | MT dose (mg/kg) | IR method | Ref. | Effect | Mechanism |
|--------|----------------|------------|------|--------|-----------|
| Rat | 20 | Intraperitoneal | 74 | Decreased the levels of ALT, AST, TNF-α, MDA, liver injury index, and apoptotic index | Increased the levels of GPs and SOD |
| Rat | 20 or 50 | Intraperitoneal | 75 | Decreased liver injury score and serum AST | Decreased the levels of inflammatory factors (TNF-α, NF-κB, IL-1β, MMP-9), decreased oxidative stress-related factors (NOX-1, NOX-2), decreased the expression of apoptosis proteins (cleaved caspase-3, PARP), decreased the release of cytosolic cytochrome c, suppressed mitochondrial permeability transition |
| Rat | 20 or 50 | Intraperitoneal | 76 | Decreased liver injury score; decreased plasma AST | Decreased the expression of inflammatory markers (ICAM-1, IL-1β, TNF-α, NF-κB, RANTES); decreased the expression of apoptosis proteins (cleaved caspase-3, PARP); decreased the expression of oxidative stress-related factors (NOX-1, NOX-2) |
| Mouse | 10 | Reduced-size LT | 87 | Enhanced inflammatory Liver + F4/80+ monocytes and promoted the release of IL-6, IL-10 and TNF-α | Enhanced inflammatory Liver + F4/80+ monocytes and promoted liver regeneration |

7 | MT TREATMENT OF COLD IR

In individuals who undergo LT, the high incidences of graft rejection and early transplant failure in LT significantly increase the need for liver retransplantation. As LT is limited by restricted liver donor sources, doctors have expanded to performing surgery with marginal liver grafts from non-heart-beating donors, older donors and steatotic liver tissues. These grafts are more vulnerable to cold IRI. Excised liver grafts are stored in preservation solutions, and some components guarantee their effectiveness, while other components have a marginal effect on liver grafts. The most common solution used to store liver grafts is University of Wisconsin (UW) solution. The storage of liver grafts is limited to 12 hours by simple hypothermia, and UW solution has various disadvantages, such as high viscosity and high concentration of K+ Institute George Lopez (IGL-1) solution was developed based on UW solution to attenuate the risk of cardiovascular complications and provide greater protection of fatty livers via attenuation of oxidative stress and mitochondrial damage. To improve the function of isolated liver grafts, effective agents such as MT were added to the preservation solution or administered to liver
donors (Figure 3). Cold-preserved livers perfused without MT showed a narrow portal region and lower ATP content, while MT preserved liver morphology and decreased ROS generation in liver tissues that underwent cold IR. Furthermore, MT preserved the liver function of excursive nonsteatotic and steatotic liver tissue, accompanied by lower transaminase levels and higher bile production and sulphobromophthalein (BSP) clearance. MT improved bile secretion but decreased the γ-glutamyl transpeptidase level, subsequently significantly improving the restoration of liver function after cold storage and reperfusion in liver grafts in a dose-dependent manner. MT was suggested to improve NO generation and inhibit oxidative stress and inflammation in liver grafts to protect against cold IR. Although steatotic livers reduce the shortage of donors for LT, they exhibit exacerbated ER stress and increase the incidence of cold IRI and graft dysfunction. The addition of MT to the preservation solution significantly attenuated hepatic injury and improved bile production in steatotic livers by decreasing the activities of glucose-regulated protein 78 kDa (GRP78), protein kinase-like endoplasmic reticulum kinase (PERK), and CHOP and upregulating autophagic marker expression and adenosine monophosphate-activated protein kinase (AMPK) phosphorylation. In addition, a cocktail consisting of MT and other drugs (pentoxifylline, glycine, deferoxamine, N-acetylcysteine, erythropoietin and simvastatin) provided effective protection against IR in steatotic liver grafts via attenuation of hepatic leucocyte infiltration, vacuolization and cell death. This multidrug treatment also decreased the levels of TNF-α and ICAM-1 and restored liver function to nearly the control level. Another multidrug cocktail based on MT, curcumin, simvastatin, N-acetylcysteine, erythropoietin, pentoxiphylline, glycine and methylprednisolone for donor preconditioning significantly improved cell membrane integrity and decreased the levels of ALT, AST and LDH in excursive liver grafts. Moreover, the multidrug pretreatment also restored bile flow and reduced the levels of TNF-α, IL-6 and MDA in the grafts. In a model with reduced-size LT, MT preserved liver function and promoted liver regeneration by enhancing inflammatory Ly6C+ F4/80+ monocytes and promoting the release of IL-6, IL-10 and TNF-α. Intriguingly, MT also had beneficial effects on patients with hepatocellular carcinoma (HCC) who underwent LT. MT increased the activity of antioxidants but decreased the level of MDA to improve their survival rate.
Warm and cold IRI in liver tissue are mediated by various mechanisms, such as mitochondrial dysfunction, liver microcirculation dysfunction and inflammation. Ischaemia initiates the generation of excessive free radicals in the liver, while reperfusion exacerbates liver injury after impairing the respiratory chain, metabolic enzymes and mitochondrial membrane structure. Consequently, IR leads to mitochondrial dysfunction, ATP depletion and the release of apoptotic factors in remnant or cold-preserved liver grafts. Although activation of autophagy serves as a protective mechanism following warm or cold IR by removing damaged intracellular contents and maintaining ATP production, excessive up-regulation of autophagy destroys essential proteins and organelles and leads to cell death in liver tissue during the severe ischaemic period. Endogenous MT is able to decrease inflammatory factors and maintain the mitochondrial redox state and mitochondrial biogenesis, consequently attenuating hepatic IRI in liver resection and LT. The evidence compiled in this review will serve as a comprehensive reference for the actions of MT in liver IRI and hopefully aid in the design of future research. MT is considered an effective agent with protective effects against hepatic IR, and there is currently a major shortage of studies on the application of MT in LT recipients. Furthermore, we highlighted strategies to improve the efficacy and safety of MT for attenuating hepatic IRI in different conditions. After the potential mechanisms underlying the interaction between MT and other important cellular processes during hepatic IR are clarified, more opportunities will be available to use MT to treat liver diseases in the future.

ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (No. 81700553), the Zhejiang Basic Public Welfare Research Program (No. LGF20H0300008) and the Independent Fund of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS

Lanjuan Li contributed to the conception of this study. Chenxia Hu and Lingfei Zhao drafted the manuscript. Chenxia Hu and Fen Zhang revised the manuscript. All authors read and approved the final manuscript.

PEER REVIEW

The peer review history for this article is available at https://publon.com/publon/10.1111/cpr.13021.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analysed in this study.

REFERENCES

1. Dar WA, Sullivan E, Bynon JS, Eltzschig H, Ju Cs. Ischaemia reperfusion injury in liver transplantation: cellular and molecular mechanisms. Liver Int. 2019;39:788-801. https://doi.org/10.1111/liv.14091
2. Saidi RF, Kenari SK. Liver ischemia/reperfusion injury: an overview. J Invest Surg. 2014;27:366-379. https://doi.org/10.3109/0894939.2014.932473
3. Abdalla EK, Vauthey JN. Steatosis as a risk factor in liver surgery. Ann Surg. 2007;246:340-341. https://doi.org/10.1097/SLA.0b013e31811ea9d2
4. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl. 2003;9:651-663. https://doi.org/10.1053/jlt.2003.50105
5. Li J, Li RJ, Lv GY, et al. The mechanisms and strategies to protect from hepatic ischemia-reperfusion injury. Eur Rev Med Pharmacol Sci. 2015;19:2036-2047.
6. van Riel WG, van Golen RF, Reiniers MJ, et al. How much ischemia can the liver tolerate during resection? Hepatobiliary Surg Nutr. 2016;5:58-71. https://doi.org/10.3978/j.issn.2304-3881.2015.07.05
7. Jaeschke H, Woolbright BL. Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. Transplant Rev (Orlando). 2012;26:103-114. https://doi.org/10.1016/j.trre.2011.10.006
8. Hu C, Zhao L, Tao J, Li L. Protective role of melatonin in early-stage and end-stage liver cirrhosis. J Cell Mol Med. 2019;23:7151-7162. https://doi.org/10.1111/jcmm.14634
9. Ren W, Liu G, Chen S, et al. Melatonin signaling in T cells: functions and applications. J Pineal Res. 2017;62:e12394. https://doi.org/10.1011/jip.12394
10. Sun H, Huang FF, Qu S. Melatonin: a potential intervention for hepatic steatosis. Lipids Health Dis. 2015;14:75. https://doi.org/10.1186/s12944-015-0081-7
11. Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes. J Pineal Res. 2013;54:127-138. https://doi.org/10.1111/j.1097-0258.2012.12026
12. Sewerynek E, Reiter RJ, Melchiorri D, et al. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. Hepatogastroenterology. 1996;43:898-905.
13. Mukherjee D, Ghosh AK, Dutta M, et al. Mechanisms of isoproterenol-induced cardiac mitochondrial damage: protective actions of melatonin. J Pineal Res. 2015;58:275-290. https://doi.org/10.1111/jpi.12213
14. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci. 2000;7:444-458. https://doi.org/10.1007/bf02253360
15. Reiter RJ, Mayo JC, Tan DX, et al. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253-278. https://doi.org/10.1111/jpi.12360
16. Manchester LC, Coto-Montes A, Boga JA, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403-419. https://doi.org/10.1111/jpi.12267
17. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol. 2006;91:807-819. https://doi.org/10.1113/epophys.2006.03506
18. Teoh NC. Hepatic ischemia reperfusion injury: contemporary perspectives on pathogenic mechanisms and basis for hepatoprotection—the good, bad and deadly. J Gastroenterol Hepatol. 2011;26(Suppl 1):180-187. https://doi.org/10.1111/j.1440-1746.2010.06584.x

ORCID

Lanjuan Li https://orcid.org/0000-0001-6945-0593
56. Lahiri DK, Ge YW, Sharman EH, Bondy SC. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxy-melatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J Pineal Res. 2004;36:217-223. https://doi.org/10.10111/j.1600-079X.2004.00120.x

57. Tan DX, Manchester LC, Esteban-Zubero E, Zhou Z, Reiter R. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. Molecules. 2015;20:18886-18906. https://doi.org/10.3390/molecules202018886

58. Venegas-C. GarcíaJA, EscamesG, et al. Extrapineal melatonin: analysis of subcellular distribution and daily fluctuations. J Pineal Res. 2012;52:217-227. https://doi.org/10.1111/j.1600-079X.2011.00931.x

59. Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014;29:325-333. https://doi.org/10.1115/physiol.00011.2014

60. Shen XD, Ke B, Zhai Y, et al. Toll-like receptor and oxygenase-1 signaling in hepatic ischemia/reperfusion injury. J Pineal Res. 2011;50:403-411. https://doi.org/10.10111/j.1600-079X.2011.00858.x

61. Kang JW, Koh EJ, Lee SM. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J Pineal Res. 2012;53:67-76. https://doi.org/10.10111/j.1600-079X.2011.00972.x

62. Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta. 2007;1773:1341-1348. https://doi.org/10.1016/j.bbamcr.2006.12.009

63. Uehara T, Bennett B, Sakata ST, et al. JNK mediates hepatic ischemia-reperfusion injury. J Hepatol. 2005;42:850-859. https://doi.org/10.1016/j.jhep.2005.01.030

64. Deng WS, Xu Q, Liu YE, Jiang CH, Zhou H, Gu L. Effects of melatonin on liver function and lipid peroxidation in a rat model of hepatic ischemia/reperfusion injury. Exp Ther Med. 2016;11:1955-1960. https://doi.org/10.3892/etm.2016.3160

65. Kim SH, Lee SM. Cytoprotective effects of melatonin against necrosis and apoptosis induced by ischemia/reperfusion injury in rat liver. J Pineal Res. 2008;44:165-171. https://doi.org/10.1111/j.1600-079X.2007.00504.x

66. Rodríguez-Reynoso S, Leal C, Portilla E, et al. Effect of exogenous melatonin on hepatic energetic status during ischemia/reperfusion: possible role of tumor necrosis factor-alpha and nitric oxide. J Surg Res. 2001;100:141-149. https://doi.org/10.1006/jsre.2001.6185

67. Liang R, Nickkholgh A, Hoffmann K, et al. Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation. J Pineal Res. 2009;46:8-14. https://doi.org/10.1111/j.1600-079X.2008.00596.x

68. Oszmy M, Gonul Y, Ozkececi ZT, et al. The protective effect of melatonin on remote organ liver ischemia and reperfusion injury following aortic clamping. Ann Ital Chir. 2016;87:271-279.

69. Zhou H, Jiang C, Gu L, Liu Ye, Sun L, Xu Q. Influence of melatonin on IL-1α gene and IL-1 expression in rats with liver ischemia reperfusion injury. Biomed Rep. 2016;4:667-672. https://doi.org/10.3892/br.2016.645

70. Gim SA, Koh PO. Melatonin attenuates hepatic ischemia through mitogen-activated protein kinase signaling. J Surg Res. 2015;198:228-236. https://doi.org/10.1016/j.jss.2015.05.043

71. Kang JW, Cho HI, Lee SM. Melatonin inhibits mTOR-dependent autophagy during liver ischemia/reperfusion. Cell Physiol Biochem. 2014;33:23-36. https://doi.org/10.1159/000356647

72. Nickkholgh A, Schneider H, Sobirey M, et al. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res. 2011;50:381-388. https://doi.org/10.1111/j.1600-079X.2011.00854.x

73. Taghizadeh M, Hajipour B, Aal DA, Khodadadi A, Somi MH, Banei M. Combination effect of melatonin and dexamethasone on liver ischemia/reperfusion injury. Bratisl Lek Listy. 2016;117:47-53.

74. Chen HH, Chen YT, Yang CC, et al. Melatonin pretreatment enhances the therapeutic effects of exogenous mitochondria against hepatic ischemia-reperfusion injury in rats through suppression of mitochondrial permeability transition. J Pineal Res. 2016;61:52-68. https://doi.org/10.1111/jpi.12326

75. Sun CK, Chen CH, Chang CL, et al. Melatonin treatment enhances therapeutic effects of exosomes against acute liver ischemia-reperfusion injury. Am J Transpl. 2017;9:1543-1560.

76. de Rougemont O, Lehmann K, Clavien PA. Preconditioning, organ preservation, and postconditioning to prevent ischemia-reperfusion injury to the liver. Liver Transpl. 2009;15:1172-1182. https://doi.org/10.1002/lt.21876

77. Clavien PA. How far can we go with marginal donors? J Hepatol. 2006;45:483-484. https://doi.org/10.1016/j.jhep.2006.07.015

78. Straatsburg IH, Abrahamse SL, Song SW, Hartman Robin J, van Gulik TM. Evaluation of rat liver apoptotic and necrotic cell death after cold storage using UW, HTK, and Celsior. Transplantation. 2002;74:458-464. https://doi.org/10.1097/00007890-200208270-00005

79. Adam R, Delwart V, Karam V, et al. Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. Am J Transplant. 2015;15:395-406. https://doi.org/10.1111/ajt.13060

80. Freitas I, Bertone V, Guarnaschelli C, et al. In situ demonstration of improvement of liver mitochondria function by melatonin after cold ischemia. In Vivo. 2006;20:229-237.

81. Vairetti M, Ferrigno A, Bertone R, et al. Exogenous melatonin enhances bileflow and ATP levels after cold storage and reperfusion. Liver-implications for liver transplantation. J Pineal Res. 2005;38:223-230. https://doi.org/10.1111/j.1600-079X.2004.00193.x

82. Zaouali MA, Reiter RJ, Padriassa-Altes S, et al. Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. J Pineal Res. 2011;50:213-221. https://doi.org/10.1111/j.1600-079X.2010.00831.x

83. Zaouali MA, Boncompagni E, Reiter RJ, et al. AMPK involvement in endoplasmic reticulum stress and autophagy modulation after fatty liver graft preservation: a role for melatonin and trimetazidine cocktail. J Pineal Res. 2013;55:65-78. https://doi.org/10.1111/jpi.12051

84. von Heessen M, Seibert K, Hülsér M, et al. Multidrug donor preconditioning protects steatotic liver grafts against ischemia-reperfusion injury. Am J Surg. 2012;203:168-176. https://doi.org/10.1016/j.amjsurg.2011.01.026

85. Moussavand MR, Scheuer C, Schmidt M, et al. Multidrug donor preconditioning prevents cold liver preservation and reperfusion injury. Langenbecks Arch Surg. 2011;396:231-241. https://doi.org/10.1007/s00423-010-0668-4

86. Song Z, Humar B, Gupta A, et al. Exogenous melatonin protects small-for-size liver grafts by promoting monocyte infiltration and releases interleukin-6. J Pineal Res. 2018;65:e12486. https://doi.org/10.1111/jpi.12486

87. Lorente L, Rodriguez ST, Sanz P, et al. Low serum melatonin levels prior to liver transplantation in patients with hepatocellular carcinoma are associated with lower survival after liver transplantation. Int J Mol Sci. 2019;20:1696. https://doi.org/10.3390/ijms20071696

How to cite this article: Hu C, Zhao L, Zhang F, Li L. Melatonin and its protective role in attenuating warm or cold hepatic ischaemia/reperfusion injury. Cell Prolif. 2021;54:e13021. https://doi.org/10.1111/cpr.13021

HU ET AL. 11 of 11